TScan Therapeutics (TCRX) Non-Current Debt (2022 - 2026)

TScan Therapeutics (TCRX) has 5 years of Non-Current Debt data on file, last reported at $32.7 million in Q1 2026.

• On a quarterly basis, Non-Current Debt rose 1.47% year-over-year to $32.7 million in Q1 2026; TTM through Mar 2026 was $32.7 million, a 1.47% increase from a year earlier, with the FY2025 full-year figure at $32.5 million, up 1.44% from the prior year.
• Non-Current Debt for Q1 2026 stood at $32.7 million, roughly flat from $32.5 million in the prior quarter.
• Over the last five years, Non-Current Debt for TCRX reached as high as $32.7 million in Q1 2026 and fell as low as $20.1 million in Q2 2024.
• Historically, Non-Current Debt has averaged $29.4 million across 5 years, with a median of $29.7 million in 2023.
• Across the five-year window, Non-Current Debt sank 32.33% in 2024 and jumped 60.58% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $29.3 million in 2022, then slipped by 8.84% to $26.7 million in 2023, then rose by 20.12% to $32.1 million in 2024, then gained by 1.44% to $32.5 million in 2025, then gained by 0.37% to $32.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $32.7 million in Q1 2026, $32.5 million in Q4 2025, and $32.4 million in Q3 2025.